Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents
出版年份 2020 全文链接
标题
Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents
作者
关键词
-
出版物
BONE MARROW TRANSPLANTATION
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-12-04
DOI
10.1038/s41409-020-01159-9
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65‐75 years
- (2020) Angelo Belotti et al. AMERICAN JOURNAL OF HEMATOLOGY
- Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management
- (2020) S. Vincent Rajkumar AMERICAN JOURNAL OF HEMATOLOGY
- Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN
- (2020) Peter M Voorhees et al. BLOOD
- Validation of the revised myeloma comorbidity index and other comorbidity scores in a multicenter German study group multiple myeloma trial
- (2020) Sandra Maria Dold et al. HAEMATOLOGICA
- The characteristics, treatment patterns, and outcomes of older adults aged 80 and over with multiple myeloma
- (2020) Mark A. Fiala et al. Journal of Geriatric Oncology
- Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
- (2020) Maria-Victoria Mateos et al. Lancet Haematology
- Tolerability of high dose chemotherapy and autologous stem cell transplantation in elderly patients with multiple myeloma: A single-center retrospective analysis
- (2020) H. Wiebach et al. Current Research in Translational Medicine
- Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials
- (2020) Saad Z Usmani et al. Lancet Haematology
- Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
- (2020) Michele Cavo et al. Lancet Haematology
- Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma
- (2020) Pashna N. Munshi et al. CANCER
- Assessing the safety of autologous stem cell transplant pathway via ambulatory care for patients with multiple myeloma
- (2020) Hao Meng Yip et al. Hematology/ Oncology and Stem Cell Therapy
- Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma
- (2019) Edward A. Stadtmauer et al. JOURNAL OF CLINICAL ONCOLOGY
- A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study
- (2019) Gordon Cook et al. Lancet Haematology
- Efficacy and safety of autologous stem cell transplantation in patients aged ≥ 65 years with multiple myeloma in the era of novel agents
- (2019) Shohei Mizuno et al. BONE MARROW TRANSPLANTATION
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
- (2019) Thierry Facon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years
- (2019) Qaiser Bashir et al. LEUKEMIA & LYMPHOMA
- Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
- (2019) Ajai Chari et al. NEW ENGLAND JOURNAL OF MEDICINE
- NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020
- (2019) Shaji K. Kumar et al. Journal of the National Comprehensive Cancer Network
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
- (2019) Michel Attal et al. LANCET
- Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
- (2019) Maria-Victoria Mateos et al. LANCET
- Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time
- (2018) M Hasib Sidiqi et al. JOURNAL OF CLINICAL ONCOLOGY
- Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma
- (2018) Carolina Marini et al. ANNALS OF HEMATOLOGY
- Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study
- (2018) Guido Ghilardi et al. BONE MARROW TRANSPLANTATION
- Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older
- (2018) Anays Murillo et al. Journal of Geriatric Oncology
- Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome
- (2018) Ashley R. Paquin et al. Blood Cancer Journal
- Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma
- (2017) Nina Shah et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives
- (2017) Francesca Gay et al. HAEMATOLOGICA
- From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives
- (2017) Francesca Gay et al. HAEMATOLOGICA
- N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma
- (2016) Paolo Milani et al. AMERICAN JOURNAL OF HEMATOLOGY
- Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
- (2016) P. Sonneveld et al. BLOOD
- High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation
- (2016) Christa E. Nath et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
- (2016) Shaji Kumar et al. LANCET ONCOLOGY
- Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
- (2015) A. Palumbo et al. BLOOD
- Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years
- (2014) H W Auner et al. BONE MARROW TRANSPLANTATION
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
- (2014) S Vincent Rajkumar et al. LANCET ONCOLOGY
- Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents
- (2013) M. Merz et al. ANNALS OF ONCOLOGY
- Assessment of Vulnerability Measures and Their Effect on Survival in a Real-Life Population of Multiple Myeloma Patients Registered at Marche Region Multiple Myeloma Registry
- (2012) Massimo Offidani et al. Clinical Lymphoma Myeloma & Leukemia
- Autologous Stem Cell Transplant in 716 Patients With Multiple Myeloma: Low Treatment-Related Mortality, Feasibility of Outpatient Transplant, and Effect of a Multidisciplinary Quality Initiative
- (2009) Morie A. Gertz et al. MAYO CLINIC PROCEEDINGS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More